Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07161037 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
A Phase 2 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 20
- Study locations
NCT07161037: Recruiting Phase 2 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated.
NCT07161037 is a Phase 2 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD) that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 24 participants, below the 787-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07161037, a Phase 2 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
Conditions Studied
Interventions
- DRUG VX-407
Study Locations (20)
Alabama
- Alabama Kidney Research - Alabaster
- University of Alabama at Birmingham- Nephrology Research Clinic - Birmingham
California
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- UCSF Clinical Research Center at Parnassus - San Francisco
Connecticut
- Nephrology & Hypertension Associates, PC - Middlebury
- Yale University - Yale Nephrology Clinical Research Clinic - New Haven
Georgia
- Emory School of Medicine - Renal Division - Atlanta
- Renal Associates - Columbus
Massachusetts
- Tufts Medical Center - Boston
- Beth Israel Deaconess Medical Center - Nephrology - Boston
Minnesota
- University of Minnesota -Clinics and Surgery Center (CSC) - Endocrine Clinic - Minneapolis
- Mayo Clinic - Rochester - Rochester
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Illinois
- UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-11-19 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT07161037 shows while recruiting
NCT07161037 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 787-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) appearing as the primary indexed condition, and to 1 intervention - of which VX-407 is the first listed.
NCT07161037 names 20 study sites across 14 states, led by Alabama, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07161037 about?
NCT07161037 is a clinical study titled "Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)". The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
What is the current status of trial NCT07161037?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2025-11-19. Estimated completion is 2027-12-31.
What conditions does trial NCT07161037 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD).
What interventions are being tested in trial NCT07161037?
The interventions under investigation include: VX-407 (DRUG).
Who is sponsoring clinical trial NCT07161037?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07161037 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
RECRUITING · NA
-
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
ACTIVE NOT RECRUITING
-
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI